*Felix Pharmaceuticals to Sell Controlling Stake in Felix Generics* *By The Valuation School* Felix Pharmaceuticals is seeking to sell a controlling stake in its subsidiary, Felix Generics, which manufactures veterinary drugs for companion pets like dogs and cats. The company is targeting a valuation of $200-250 million and has appointed investment bank Lincoln International to facilitate the deal. Discussions are underway with mid-sized buyout and growth-stage private equity firms, with the transaction expected to close by the next quarter. *Purpose of the Sale* The deal will provide Felix Pharmaceuticals with capital to expand its product range in animal health, nutrition, and wellness while allowing the founders a partial exit. Despite selling a majority stake, the company plans to retain a significant share and continue managing operations alongside the new investor. *Manufacturing and Regulatory Approvals* Felix Generics, established in 2015, operates a manufacturing facility at Pithampur SEZ in Indore, Madhya Pradesh. The plant produces tablets, chewables, injectables, oral liquids, and pastes, with an annual capacity of 150 million tablets. It has received regulatory approvals from the Health Product Regulatory Authority (HPRA) in Ireland and the US Food and Drug Administration (USFDA). *Growth in the Pet Healthcare Market* India’s pet healthcare industry is expanding rapidly due to increasing pet ownership, driving demand for veterinary drugs and wellness products. Several startups in this space, such as Wiggles, Heads Up For Tails, Drools, and Benny’s Bowl, have attracted institutional investors. *Future Outlook* Felix Generics primarily serves the US market and is projected to grow at a compound annual growth rate (CAGR) of 30-40% as it scales operations and expands its product portfolio. The sale of a controlling stake positions the company to capitalize on this growth and strengthen its market presence. *Acha laga, react & share karo & follow our social media for more updates & financial content:* ✅ WhatsApp Channel: https://t.ly/BJTRY ✅ Youtube: https://t.ly/lJqST ✅ Newsletter: https://t.ly/L2vK2 ✅ Instagram: https://t.ly/SLIX4 ✅ LinkedIn (Parth Sir): https://t.ly/mN4yj ✅ LinkedIn (The Valuation School): https://t.ly/Hbeh0 *Note:* This post is just for educational purposes and not a buy/sell recommendation.